Dr Hemberger is currently a director of Zymogenetics, Chroma, Atani and Zosano Pharma. Previously, she was a director at Marion Merrell Dow, NeXstar Pharmaceuticals, Pharmion, Perrigo, Myogen and Novacca.
Lee Southard, CEO of VasoGenix, said: “Dr Hemberger is a seasoned pharmaceutical executive who will be important to the growth of VasoGenix as we develop our new calcitonin gene related peptide agonist analogs to treat heart failure.
“Her tremendous experience in drug development and finance will be of great help in guiding VasoGenix into the future. Particularly in this difficult economic time, VasoGenix is very fortunate to have Judy Hemberger join its board of directors.”